Functional interactions of the SPAK/OSR1 kinases with their upstream activator WNK1 and downstream substrate NKCC1

• Published in: Biochemical journal Vol. 397; no. 1; pp. 223 - 231
• Main Authors: Vitari, Alberto C, Thastrup, Jacob, Rafiqi, Fatema H, Deak, Maria, Morrice, Nick A, Karlsson, Håkan K R, Alessi, Dario R
• Format: Journal Article
• Language: English
• Published: England Portland Press 01-07-2006; Portland Press Ltd
• Subjects: Binding Sites; Cells, Cultured; Enzyme Activation; Humans; Hyperkalemia - genetics; Hypertension - genetics; Intracellular Signaling Peptides and Proteins; Kidney - cytology; Minor Histocompatibility Antigens; Mutation; Osmolar Concentration; Phosphorylation; Protein-Serine-Threonine Kinases - metabolism; Sequence Homology, Amino Acid; Serine; Sodium-Potassium-Chloride Symporters; Solute Carrier Family 12, Member 2; Substrate Specificity; Threonine; Transcription Factors - metabolism; WNK Lysine-Deficient Protein Kinase 1; Life Sciences
• ISSN: 0264-6021; 1470-8728
• DOI: 10.1042/BJ20060220

The SPAK (STE20/SPS1-related proline/alanine-rich kinase) and OSR1 (oxidative stress-responsive kinase-1) kinases interact and phosphorylate NKCC1 (Na+-K+-2Cl- co-transporter-1), leading to its activation. Recent studies indicated that SPAK and OSR1 are phosphorylated and activated by the WNK1 [with no K (lysine) protein kinase-1] and WNK4, genes mutated in humans affected by Gordon's hypertension syndrome. In the present study, we have identified three residues in NKCC1 (Thr175/Thr179/Thr184 in shark or Thr203/Thr207/Thr212 in human) that are phosphorylated by SPAK and OSR1, and have developed a peptide substrate, CATCHtide (cation chloride co-transporter peptide substrate), to assess SPAK and OSR1 activity. Exposure of HEK-293 (human embryonic kidney) cells to osmotic stress, which leads to phosphorylation and activation of NKCC1, increased phosphorylation of NKCC1 at the sites targeted by SPAK/OSR1. The residues on NKCC1, phosphorylated by SPAK/OSR1, are conserved in other cation co-transporters, such as the Na+-Cl- co-transporter, the target of thiazide drugs that lower blood pressure in humans with Gordon's syndrome. Furthermore, we characterize the properties of a 92-residue CCT (conserved C-terminal) domain on SPAK and OSR1 that interacts with an RFXV (Arg-Phe-Xaa-Val) motif present in the substrate NKCC1 and its activators WNK1/WNK4. A peptide containing the RFXV motif interacts with nanomolar affinity with the CCT domains of SPAK/OSR1 and can be utilized to affinity-purify SPAK and OSR1 from cell extracts. Mutation of the arginine, phenylalanine or valine residue within this peptide abolishes binding to SPAK/OSR1. We have identified specific residues within the CCT domain that are required for interaction with the RFXV motif and have demonstrated that mutation of these in OSR1 inhibited phosphorylation of NKCC1, but not of CATCHtide which does not possess an RFXV motif. We establish that an intact CCT domain is required for WNK1 to efficiently phosphorylate and activate OSR1. These data establish that the CCT domain functions as a multipurpose docking site, enabling SPAK/OSR1 to interact with substrates (NKCC1) and activators (WNK1/WNK4).